company background image
GEM logo

GeNeuro DB:GEM Stock Report

Last Price

€0.081

Market Cap

€2.8m

7D

-22.3%

1Y

-92.0%

Updated

06 Mar, 2025

Data

Company Financials

GEM Stock Overview

A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More details

GEM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

GeNeuro SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for GeNeuro
Historical stock prices
Current Share Price€0.081
52 Week High€2.42
52 Week Low€0.027
Beta0.48
1 Month Change-40.51%
3 Month Change165.36%
1 Year Change-92.00%
3 Year Change-97.43%
5 Year Change-96.88%
Change since IPO-99.32%

Recent News & Updates

Recent updates

Shareholder Returns

GEMDE BiotechsDE Market
7D-22.3%-3.7%3.3%
1Y-92.0%-17.9%18.1%

Return vs Industry: GEM underperformed the German Biotechs industry which returned -15.8% over the past year.

Return vs Market: GEM underperformed the German Market which returned 17.1% over the past year.

Price Volatility

Is GEM's price volatile compared to industry and market?
GEM volatility
GEM Average Weekly Movement173.7%
Biotechs Industry Average Movement9.6%
Market Average Movement5.2%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.8%

Stable Share Price: GEM's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: GEM's weekly volatility has increased from 101% to 174% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200617Jesus Martin-Garciawww.geneuro.com

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program.

GeNeuro SA Fundamentals Summary

How do GeNeuro's earnings and revenue compare to its market cap?
GEM fundamental statistics
Market cap€2.80m
Earnings (TTM)-€14.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GEM income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€14.76m
Earnings-€14.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.50
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-93.4%

How did GEM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/06 19:21
End of Day Share Price 2025/03/06 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GeNeuro SA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric Le BerrigaudBryan Garnier & Co
Stephanie LefebvreGilbert Dupont
Delphine Le LouetSociete Generale Cross Asset Research